Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 8Thoracic 3Gastrointestinal 2Breast 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 9Triple Negative Breast Neoplasms 8Lung Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Neoplasms 3Mesothelioma 3Lymphoma 3Head and Neck Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2NSCLC 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × spartalizumab × Thoracic × Clear all
NCT03058289 2025-02-27

IT-01

Intensity Therapeutics, Inc.

Phase 1/2 Completed
111 enrolled 21 charts
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03393858 2024-02-07

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Capital Medical University

Phase 1/2 Terminated
10 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Neoplasms

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔